Skip to content
Review Open access

Sleep–neuroinflammation interactions in Alzheimer’s disease: a systematic review of biomarker pathways

Sep 2026 · Frontiers in Aging Neuroscience · Vol 18 · 0 citations · 66 references
Medicine

TL;DR

The available evidence supports a biologically plausible, potentially bidirectional relationship between sleep disruption and AD pathology, while highlighting important gaps in translation.

Abstract

Although sleep disturbances are increasingly associated with Alzheimer’s disease (AD), the mechanistic interplay between sleep physiology, neuroinflammation and AD-related pathology is not fully understood. The question of whether disrupted sleep contributes to neurodegeneration or merely reflects early pathological processes is still being debated. In accordance with PRISMA-2020 guidelines, we conducted a systematic review to synthesize the current evidence linking objectively measured sleep alterations, glial activation and AD-related outcomes. A comprehensive search of PubMed, Scopus, EMBASE and Web of Science (January 2000 – June 2026) identified 40 original studies that met the predefined inclusion criteria. These studies included objective sleep assessments (polysomnography, electroencephalography, actigraphy, or experimental sleep manipulation), direct evaluations of neuroinflammatory or glial markers, and assessments of amyloid-β (Aβ), tau pathology, neurodegeneration and cognition. Human studies indicate that slow-wave sleep impairment, sleep fragmentation, and REM sleep dysregulation are linked to neuroinflammation and AD-related pathology. Further mechanistic insights come from experimental animal and translational studies, which show that sleep deprivation or disruption may enhance microglial activation, astrocytic reactivity, and the accumulation of AD-related proteins. However, limited prior work has integrated evidence from sleep physiology, central neuroinflammatory measures, and multimodal AD biomarkers in humans. The available evidence supports a biologically plausible, potentially bidirectional relationship between sleep disruption and AD pathology, while highlighting important gaps in translation. Further longitudinal and interventional investigations are required to clarify causality and determine whether targeting sleep physiology could meaningfully influence disease trajectories.

Read PDF

Similar papers

Review Open access Oct 2026

Sleep Loss and Alzheimer’s Disease: Mechanisms, Risk Factors, and Cognitive Consequences—A Narrative Review

Sleep loss is increasingly recognized as a potentially modifiable factor in cognitive aging and Alzheimer’s disease (AD). Evidence supports a bidirectional relationship in which sleep disruption may both reflect early AD-related neurodegenerative changes and contribute to disease progression. This narrative review them...

Antoniya Hachmeriyan, G. Panayotova, Annriya Anand et al. · 0 citations
Review Open access Sep 2026

Sleep and stress as modifiable drivers of Alzheimer’s disease

Proper sleep and stress maintenance are essential for health and may contribute to disease progression when dysregulated. This review highlights the intricate links between sleep, stress, and Alzheimer’s disease, including underlying neural circuitry and mechanisms that contribute to disease. Sleep is essential for pro...

Darcy Wear, S. A. Hussaini, Wai Haung Yu · 0 citations
Review Open access Sep 2026

Chronic Sleep Restriction as a Modifiable Risk Factor for Alzheimer’s Disease: A Narrative Review on Hippocampal Memory Consolidation, Amyloid-β Pathology, and Epidemiological Evidence

Chronic sleep restriction has become increasingly prevalent and has emerged as a potentially modifiable factor associated with cognitive decline and Alzheimer’s disease (AD). This narrative review synthesized current neuroscientific, clinical, and epidemiological evidence examining the relationship between habitual sle...

Zehra Hussain, Ayesha Babar Ayesha Babar, Imaan Siddiqui et al. · 0 citations
Review Open access Sep 2026

Alzheimer’s Disease in the Era of Geroscience: Mechanisms, Biomarkers, and Therapeutic Prospects

Alzheimer’s disease (AD) is the leading cause of dementia and a heterogeneous neurodegenerative disorder characterized by amyloid-β (Aβ) and tau pathology, impaired proteostasis, neurovascular dysfunction, maladaptive glial and immune responses, and synaptic dysfunction. Human genetic evidence supports an upstream role...

P. Chmielewski · 0 citations
Review Open access Aug 2026

Nutritional modulation of neuroinflammation in Alzheimer’s disease and mild cognitive impairment: a systematic review of clinical and preclinical evidence

Neuroinflammationis a key contributor to the pathogenesis of Alzheimer’s disease (AD) and mild cognitive impairment (MCI). Nutritional interventions have been proposed as potential modulators of neuroinflammatory pathways; however, the consistency and strength of the available evidence remain uncertain. This systematic...

Mahmoud Al Sayed, Ahmed H. M. Said, M. Meselhy · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.